Literature DB >> 28611136

A rare case of Mycobacterium abscessus subspecies abscessus prosthetic valve endocarditis and the clinical importance of inducible erm(41) gene testing.

Norman Beatty1, Craig Brown1, Tirdad Zangeneh1, Mayar Al Mohajer2.   

Abstract

A 56-year-old man with a history of injection drug use and two prior episodes of native valve infective endocarditis presented with dyspnoea on exertion. Our preliminary work-up revealed bacteraemia with reported growth of 'Mycobacterium abscessus group' on multiple blood cultures. The patient was later found to have eustachian valve and prosthetic pulmonic valve endocarditis. Initially, he responded to standard antimycobacterial therapy for rapidly growing mycobacteria (RGM) with supporting laboratory susceptibilities. However, he later developed refractory disease and persistent bacteraemia in the setting of these alleged susceptible antibiotics. Further molecular testing revealed a functional and inducible erm(41) gene which confers macrolide resistance. A subspecies analysis of the M abscessus group revealed the subspecies to be abscessus We present a challenging case of M abscessus subsp. abscessus bacteraemia and prosthetic valve endocarditis with further discussion on treatment and management of this infection along with the taxonomic complexity of this ubiquitous RGM. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Drugs: infectious diseases; Infections; Medical management; Valvar diseases

Mesh:

Substances:

Year:  2017        PMID: 28611136      PMCID: PMC5534681          DOI: 10.1136/bcr-2017-219618

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp.

Authors:  M MOORE; J B FRERICHS
Journal:  J Invest Dermatol       Date:  1953-02       Impact factor: 8.551

Review 2.  Rapidly growing mycobacterial bloodstream infections.

Authors:  Gilbert El Helou; George M Viola; Ray Hachem; Xiang Y Han; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2013-02       Impact factor: 25.071

3.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

Review 5.  Mycobacterium abscessus. "Pleased to meet you, hope you guess my name...".

Authors:  David E Griffith; Barbara A Brown-Elliott; Jeana L Benwill; Richard J Wallace
Journal:  Ann Am Thorac Soc       Date:  2015-03

Review 6.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 7.  Mycobacterium abscessus subsp abscessus lung disease: 'trouble ahead, trouble behind…'.

Authors:  David E Griffith
Journal:  F1000Prime Rep       Date:  2014-11-04

8.  Mycobacterium abscessus Complex Infections in Humans.

Authors:  Meng-Rui Lee; Wang-Huei Sheng; Chien-Ching Hung; Chong-Jen Yu; Li-Na Lee; Po-Ren Hsueh
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

  8 in total
  1 in total

1.  Disseminated Mycobacterium abscessus Infection Secondary to an Infected Vascular Stent: Case Report and Review of the Literature.

Authors:  Nilesh Tejura; Gilda Bontempo; Debra Chew
Journal:  Open Forum Infect Dis       Date:  2018-08-23       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.